Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma

Next Previous
X
Search
Trial Profile

A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Salbutamol
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 12 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 26 Jul 2018 Planned End Date changed from 1 Aug 2019 to 24 Jun 2019.
    • 26 Jul 2018 Planned primary completion date changed from 1 Aug 2019 to 24 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top